On December 22, 2020 Cytocom, Inc., a leading biopharmaceutical company creating second generation immune therapies, reported that the company is participating in Biotech Showcase Digital and H.C. Wainwright BioConnect (Press release, Cytocom, DEC 22, 2020, https://www.cytocom.com/2020/12/22/cytocom-to-participate-in-biotech-showcase-and-h-c-wainwright-bioconnect-2021/?utm_source=rss&utm_medium=rss&utm_campaign=cytocom-to-participate-in-biotech-showcase-and-h-c-wainwright-bioconnect-2021 [SID1234573199]). Both events will be held virtually and are scheduled alongside the J.P. Morgan 39th Annual Healthcare Conference 2021.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the events are as follows:
Event: Biotech Showcase Digital
Date: January 11-15, 2021
Registration: https://informaconnect.com/biotech-showcase/registration-options/
Event: H.C. Wainwright BioConnect 2021 Conference
Date: January 11-14, 2021
Registration: View Source
During both events, members of the Cytocom management team will participate in virtual one-on-one meetings with registered investors and pharmaceutical companies to discuss Cytocom’s business and highlight recent corporate achievements, as well as anticipated near-term milestones.
Cytocom’s two lead investigative compounds, CYTO-201 for the treatment of Crohn’s disease and CYTO-401 for the treatment of pancreatic cancer, are expected to enter Phase 3 clinical trials in 2021. In July 2020, Cytocom announced an agreement to acquire ImQuest Life Sciences, Inc., a drug development company and contract research organization. The company followed in October with a definitive merger agreement with Cleveland Biolabs, Inc. (Nasdaq: CBLI) and plans for a subsequent listing on Nasdaq Capital Market.